Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market ...

Cencora COR saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 78. Please watch ...

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results ...

Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

TD Cowen analyst Charles Rhyee maintained a Buy rating on Cencora today and set a price target of $350.00. The company’s shares closed yesterday at $283.78. Elevate Your Investi ...

Healthcare distributor Cencora (NYSE:COR) reported Q2 CY2025 results , with sales up 8.7% year on year to $80.66 billion. Its ...

Readers hoping to buy Cencora, Inc. (NYSE:COR) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and ...

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

Shares of Cencora Inc. COR slipped 1.96% to $286.08 Thursday, on what proved to be an all-around rough trading session for ...